179 related articles for article (PubMed ID: 24486585)
41. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
42. Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.
Lin YC; Wu MH; Wei TT; Chuang SH; Chen KF; Cheng AL; Chen CC
Neoplasia; 2012 Jun; 14(6):463-75. PubMed ID: 22787428
[TBL] [Abstract][Full Text] [Related]
43. Ophiopogonin B suppresses the metastasis and angiogenesis of A549 cells in vitro and in vivo by inhibiting the EphA2/Akt signaling pathway.
Chen M; Hu C; Guo Y; Jiang R; Jiang H; Zhou Y; Fu H; Wu M; Zhang X
Oncol Rep; 2018 Sep; 40(3):1339-1347. PubMed ID: 29956803
[TBL] [Abstract][Full Text] [Related]
44. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas.
Chee CE; Krishnamurthi S; Nock CJ; Meropol NJ; Gibbons J; Fu P; Bokar J; Teston L; O'Brien T; Gudena V; Reese A; Bergman M; Saltzman J; Wright JJ; Dowlati A; Brell J
Oncologist; 2013; 18(10):1091-2. PubMed ID: 24072218
[TBL] [Abstract][Full Text] [Related]
46. Epithelial tissue hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901.
Torti VR; Wojciechowicz D; Hu W; John-Baptiste A; Evering W; Troche G; Marroquin LD; Smeal T; Yamazaki S; Palmer CL; Burns-Naas LA; Bagrodia S
Mol Cancer Ther; 2012 Oct; 11(10):2274-83. PubMed ID: 22752429
[TBL] [Abstract][Full Text] [Related]
47. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
48. Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors.
Jaiswal BS; Janakiraman V; Kljavin NM; Eastham-Anderson J; Cupp JE; Liang Y; Davis DP; Hoeflich KP; Seshagiri S
PLoS One; 2009 May; 4(5):e5717. PubMed ID: 19492075
[TBL] [Abstract][Full Text] [Related]
49. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.
Paraiso KH; Das Thakur M; Fang B; Koomen JM; Fedorenko IV; John JK; Tsao H; Flaherty KT; Sondak VK; Messina JL; Pasquale EB; Villagra A; Rao UN; Kirkwood JM; Meier F; Sloot S; Gibney GT; Stuart D; Tawbi H; Smalley KS
Cancer Discov; 2015 Mar; 5(3):264-73. PubMed ID: 25542447
[TBL] [Abstract][Full Text] [Related]
50. miR-7 reverses the resistance to BRAFi in melanoma by targeting EGFR/IGF-1R/CRAF and inhibiting the MAPK and PI3K/AKT signaling pathways.
Sun X; Li J; Sun Y; Zhang Y; Dong L; Shen C; Yang L; Yang M; Li Y; Shen G; Tu Y; Tao J
Oncotarget; 2016 Aug; 7(33):53558-53570. PubMed ID: 27448964
[TBL] [Abstract][Full Text] [Related]
51. Potential Targets' Analysis Reveals Dual PI3K/mTOR Pathway Inhibition as a Promising Therapeutic Strategy for Uterine Leiomyosarcomas-an ENITEC Group Initiative.
Cuppens T; Annibali D; Coosemans A; Trovik J; Ter Haar N; Colas E; Garcia-Jimenez A; Van de Vijver K; Kruitwagen RP; Brinkhuis M; Zikan M; Dundr P; Huvila J; Carpén O; Haybaeck J; Moinfar F; Salvesen HB; Stukan M; Mestdagh C; Zweemer RP; Massuger LF; Mallmann MR; Wardelmann E; Mints M; Verbist G; Thomas D; Gommé E; Hermans E; Moerman P; Bosse T; Amant F
Clin Cancer Res; 2017 Mar; 23(5):1274-1285. PubMed ID: 28232476
[No Abstract] [Full Text] [Related]
52. Inhibition of the CRAF/prohibitin interaction reverses CRAF-dependent resistance to vemurafenib.
Doudican NA; Orlow SJ
Oncogene; 2017 Jan; 36(3):423-428. PubMed ID: 27321184
[TBL] [Abstract][Full Text] [Related]
53. The Src and c-Kit kinase inhibitor dasatinib enhances p53-mediated targeting of human acute myeloid leukemia stem cells by chemotherapeutic agents.
Dos Santos C; McDonald T; Ho YW; Liu H; Lin A; Forman SJ; Kuo YH; Bhatia R
Blood; 2013 Sep; 122(11):1900-13. PubMed ID: 23896410
[TBL] [Abstract][Full Text] [Related]
54. Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40.
Yang Y; Liu C; Peng W; Lizée G; Overwijk WW; Liu Y; Woodman SE; Hwu P
Blood; 2012 Nov; 120(23):4533-43. PubMed ID: 22936666
[TBL] [Abstract][Full Text] [Related]
55. Predictive biomarkers for dasatinib treatment in melanoma.
Eustace AJ; Kennedy S; Larkin AM; Mahgoub T; Tryfonopoulos D; O'Driscoll L; Clynes M; Crown J; O'Donovan N
Oncoscience; 2014; 1(2):158-66. PubMed ID: 25594008
[TBL] [Abstract][Full Text] [Related]
56. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
Lu H; Liu S; Zhang G; Bin Wu ; Zhu Y; Frederick DT; Hu Y; Zhong W; Randell S; Sadek N; Zhang W; Chen G; Cheng C; Zeng J; Wu LW; Zhang J; Liu X; Xu W; Krepler C; Sproesser K; Xiao M; Miao B; Liu J; Song CD; Liu JY; Karakousis GC; Schuchter LM; Lu Y; Mills G; Cong Y; Chernoff J; Guo J; Boland GM; Sullivan RJ; Wei Z; Field J; Amaravadi RK; Flaherty KT; Herlyn M; Xu X; Guo W
Nature; 2017 Oct; 550(7674):133-136. PubMed ID: 28953887
[TBL] [Abstract][Full Text] [Related]
57. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
58. Raf kinases in cancer-roles and therapeutic opportunities.
Maurer G; Tarkowski B; Baccarini M
Oncogene; 2011 Aug; 30(32):3477-88. PubMed ID: 21577205
[TBL] [Abstract][Full Text] [Related]
59. A MEK-independent role for CRAF in mitosis and tumor progression.
Mielgo A; Seguin L; Huang M; Camargo MF; Anand S; Franovic A; Weis SM; Advani SJ; Murphy EA; Cheresh DA
Nat Med; 2011 Nov; 17(12):1641-5. PubMed ID: 22081024
[TBL] [Abstract][Full Text] [Related]
60. BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.
Chen B; Tardell C; Higgins B; Packman K; Boylan JF; Niu H
PLoS One; 2012; 7(8):e42598. PubMed ID: 22880048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
